Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.44 |
| ▸ | POLR1A | O95602 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21880100 | 0.90 | USP30 (0.43) | USP30POLR1AFPR3FPR2PARP1 | |
| SCHEMBL21880092 | 0.88 | USP30 (0.41) | USP30POLR1AFPR3FPR2PARP1 | |
| SCHEMBL23930984 | 0.87 | USP30 (0.40) | USP30POLR1APARP1HDAC4HDAC6 | |
| SCHEMBL21879895 | 0.86 | USP30 (0.39) | USP30POLR1APARP1HDAC4HDAC6 | |
| SCHEMBL21879973 | 0.85 | USP30 (0.39) | USP30POLR1APARP1HDAC4HDAC6 | |
| SCHEMBL23930967 | 0.82 | USP30 (0.49) | USP30POLR1APARP1ADORA2AADORA2B | |
| SCHEMBL29902371 | 0.80 | USP30 (0.47) | USP30POLR1AFPR3FPR2PARP1 | |
| SCHEMBL23931020 | 0.77 | GABRA5 (0.36) | USP30POLR1APARP1HDAC4HDAC6 | |
| SCHEMBL21880034 | 0.77 | ADORA2A (0.38) | USP30POLR1APARP1HDAC4HDAC6 | |
| SCHEMBL23930993 | 0.77 | PIK3CD (0.39) | USP30POLR1APARP1HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021215545-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |